DrugDashboards

Temozolomide

Temozolomide · TEMOZOLOMIDE 20 mg/1 · Capsule · Oral · Ascend Laboratories, LLC

NDC 67877-0538-07 · 5 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 79% in a year, to $0.8798 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.8798per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$52.06per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$2.68per CAPweighted avg manufacturer price $1.5335 · Aug 1, 2026305% of what pharmacies pay — higher than 90% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$2.00$4.00$6.00Aug 2024Sep 2026$0.8798
14 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$26.39
#90 count
$79.18

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$5,644
68 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

23Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • Class I/II recall on same molecule/form in past 12 months+8
  • price down 79% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for temozolomide (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA207658
TE code
AB
Approval date
Apr 26, 2017
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
  • Class II · TerminatedJul 16, 2019
    Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Manufacturers of Temozolomide (Capsule)

LabelerStrengthFirst seenLast seen
Accord Healthcare Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Temozolomide — NDC 67877-0538-07," retrieved September 3, 2026, https://drugdashboards.com/drug/67877053807.

Free to cite with attribution — see how the data is put together.